RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis
Prostate cancer is the third leading cause of male cancer deaths in the developed world. The current lack of highly specific detection methods and efficient therapeutic agents for advanced disease have been identified as problems requiring further research. The integrins play a vital role in the cro...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2012-10-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2072-6694/4/4/1106 |
| _version_ | 1797724876852690944 |
|---|---|
| author | Helen M. Sheldrake Steven D. Shnyder Andrew Gordon Mark Sutherland Laurence H. Patterson |
| author_facet | Helen M. Sheldrake Steven D. Shnyder Andrew Gordon Mark Sutherland Laurence H. Patterson |
| author_sort | Helen M. Sheldrake |
| collection | DOAJ |
| description | Prostate cancer is the third leading cause of male cancer deaths in the developed world. The current lack of highly specific detection methods and efficient therapeutic agents for advanced disease have been identified as problems requiring further research. The integrins play a vital role in the cross-talk between the cell and extracellular matrix, enhancing the growth, migration, invasion and metastasis of cancer cells. Progression and metastasis of prostate adenocarcinoma is strongly associated with changes in integrin expression, notably abnormal expression and activation of the β3 integrins in tumour cells, which promotes haematogenous spread and tumour growth in bone. As such, influencing integrin cell expression and function using targeted therapeutics represents a potential treatment for bone metastasis, the most common and debilitating complication of advanced prostate cancer. In this review, we highlight the multiple ways in which RGD-binding integrins contribute to prostate cancer progression and metastasis, and identify the rationale for development of multi-integrin antagonists targeting the RGD-binding subfamily as molecularly targeted agents for its treatment. |
| first_indexed | 2024-03-12T10:23:09Z |
| format | Article |
| id | doaj.art-ec84a1c2681e4df8b0e671314986e998 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T10:23:09Z |
| publishDate | 2012-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-ec84a1c2681e4df8b0e671314986e9982023-09-02T09:59:23ZengMDPI AGCancers2072-66942012-10-01441106114510.3390/cancers4041106RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone MetastasisHelen M. SheldrakeSteven D. ShnyderAndrew GordonMark SutherlandLaurence H. PattersonProstate cancer is the third leading cause of male cancer deaths in the developed world. The current lack of highly specific detection methods and efficient therapeutic agents for advanced disease have been identified as problems requiring further research. The integrins play a vital role in the cross-talk between the cell and extracellular matrix, enhancing the growth, migration, invasion and metastasis of cancer cells. Progression and metastasis of prostate adenocarcinoma is strongly associated with changes in integrin expression, notably abnormal expression and activation of the β3 integrins in tumour cells, which promotes haematogenous spread and tumour growth in bone. As such, influencing integrin cell expression and function using targeted therapeutics represents a potential treatment for bone metastasis, the most common and debilitating complication of advanced prostate cancer. In this review, we highlight the multiple ways in which RGD-binding integrins contribute to prostate cancer progression and metastasis, and identify the rationale for development of multi-integrin antagonists targeting the RGD-binding subfamily as molecularly targeted agents for its treatment.http://www.mdpi.com/2072-6694/4/4/1106integrinRGDprostate carcinomabone metastasis |
| spellingShingle | Helen M. Sheldrake Steven D. Shnyder Andrew Gordon Mark Sutherland Laurence H. Patterson RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis Cancers integrin RGD prostate carcinoma bone metastasis |
| title | RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis |
| title_full | RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis |
| title_fullStr | RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis |
| title_full_unstemmed | RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis |
| title_short | RGD-Binding Integrins in Prostate Cancer: Expression Patterns and Therapeutic Prospects against Bone Metastasis |
| title_sort | rgd binding integrins in prostate cancer expression patterns and therapeutic prospects against bone metastasis |
| topic | integrin RGD prostate carcinoma bone metastasis |
| url | http://www.mdpi.com/2072-6694/4/4/1106 |
| work_keys_str_mv | AT helenmsheldrake rgdbindingintegrinsinprostatecancerexpressionpatternsandtherapeuticprospectsagainstbonemetastasis AT stevendshnyder rgdbindingintegrinsinprostatecancerexpressionpatternsandtherapeuticprospectsagainstbonemetastasis AT andrewgordon rgdbindingintegrinsinprostatecancerexpressionpatternsandtherapeuticprospectsagainstbonemetastasis AT marksutherland rgdbindingintegrinsinprostatecancerexpressionpatternsandtherapeuticprospectsagainstbonemetastasis AT laurencehpatterson rgdbindingintegrinsinprostatecancerexpressionpatternsandtherapeuticprospectsagainstbonemetastasis |